Phase 2 N=13 Avastin Plus Rituximab for Patients With B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Number of Participants With Response (Complete Response or Progressive Disease) — 2; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Study of Capivasertib in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 18.8; 33.3; 30.0 Percentage of Patients
Phase 2 N=9 Phase 2 Study of Bexxar in Relapsed/Refractory DLCL
Lymphoma
Primary: Clinical Response Rate — 2; 0; 1; 1 participants
Phase 2 N=25 Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate = Complete and Partial Response at 12 Weeks. — 5; 3; 2; 15 participants
Phase 2 N=64 Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Diffuse Large B-Cell Lymphoma
Primary: Overall Response (OR) Rate — 36 Participants
Phase 2 N=71 CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Overall Response Rate (Complete and Partial Responses) as Defined by the International Workshop Criteria — 62.5; 52.4 percentage of patients
Phase 3 N=358 Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)
Lymphoma, Non-Hodgkin
Primary: Kaplan Meier Estimate of Progression Free Survival Assessed by the Independent Review Committee (IRC) According to the 2007 International Working Group Response Criteria…
Phase 2 N=42 Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Lymphoma
Primary: Complete Response Rate at 20 Weeks — 45 percentage of participants
Phase 2 N=20 Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma
Recurrent Transformed B-Cell Non-Hodgkin Lymphoma · Refractory Transformed B-Cell Non-Hodgkin Lymphoma
Primary: Overall Response Rate (Combined Complete Response + Partial Response) — 6 Participants
Phase 2 N=50 Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)
Non-Hodgkins Lymphoma
Primary: Percentage of Participants With Response — 34.7 percentage of participants
Phase 3 N=503 Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Phase 2 N=53 Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Recurrent Mantle Cell Lymphoma
Primary: Number of Participants With an Overall Response Defined as Complete Response and Partial Response — 21 participants
Phase 3 N=849 Chemotherapy Before Autologous Stem Cell Transplantation +/- Rituximab in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Lymphoma
Primary: Response Rate of Patients After 2 Courses of Chemotherapy — 45.2; 44.0 percentage of response — p=0.005
Phase 2 N=72 Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants
Phase 3 N=676 Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma
Primary: Progression Free Survival — 389; 334 days — p=0.039
Phase 2 N=51 Ixabepilone in Treating Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Recurrent Adult Burkitt Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma
Primary: Objective Overall Response Rate — 14; 0 participants — p=0.022
Phase 2 N=79 Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Maximum Tolerated Dose — 1.8; 1.5 mg/m^2 of Bortezomib
N/A N=158 Prognostic Value of Clinical and Biological Factors in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: R-IPI Index (Revised International Prognostic Index) — 3.4; 32.2; 64.4 percentage of participants
Phase 2 N=60 R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial
Non-Hodgkin's Lymphoma
Primary: Response Rate — 57; 35 Participants
Phase 2 N=134 Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Relapsed Diffuse Large B-Cell Lymphoma · Refractory Diffuse Large B-Cell Lymphoma
Primary: Phase 1b: Recommended Phase 2 Dose of Lenalidomide in Combination With Fixed Doses of Ibrutinib and Rituximab in Participants With Relapsed or Refractory Diffuse Large B…
Phase 2 N=97 Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to Rituximab
Lymphoma
Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29
Phase 2 N=59 Lenalidomide Therapy After Chemotherapy & Stem Cell Transplant in Treating Chemotherapy Resistan Non-Hodgkin Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative · Recurrent Anaplastic Large Cell Lymphoma · Recurrent Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide (Phase I) — 10 milligrams PO daily
Phase 2 N=50 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas
Follicular Lymphoma · Marginal Zone B-Cell Lymphoma · MALT Lymphoma
Primary: Response Rate to Lenalidomide-dexamethasone + Rituximab Therapy in Relapsed Small B-cell Lymphoma With Rituximab Resistance — 14; 13 Participants
Phase 2 N=35 Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Diffuse Large B Cell Lymphoma Relapsed · Diffuse Large B Cell Lymphoma Refractory
Primary: Number of Participants With Dose-Limiting Toxicities as a Measure of Safety and Tolerability — 0; 0; 0; 1 Participants
Phase 2 N=48 Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell Lymphoma
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
Phase 2 N=22 Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma
Mantle Cell Lymphoma · Recurrent Diffuse Large B-Cell Lymphoma · Recurrent Follicular Lymphoma
Primary: Treatment-related Mortality Within 30 Days (TRM30) — 0 Participants
Phase 1 N=48 BI 836826 Dose Escalation in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)
Lymphoma, Non-Hodgkin
Primary: Determination of the Maximum Tolerated Dose (MTD) Based on the Occurrence of Dose-limiting Toxicity (DLT) in First Cycle in Caucasian Patients — 100 Milligram (mg)
Phase 2 N=25 Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
Non-Hodgkin's Lymphoma · Mantle Cell Lymphoma
Primary: Overall Response Rate — 40; 55; 29 percentage of patients
N/A N=41 A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular Lymphoma
Lymphoma, Follicular
Primary: Percentage of Participants With Objective Response — 92.3 percentage of participants
Phase 2 N=55 A Study of Oral LY317615 in Relapsed or Refractory Diffuse Large B-Cell Lymphomas.
Non-Hodgkin's Lymphoma
Primary: Percentage of Participants With Relapsed or Refractory DLBCL Who Are Progression-Free for at Least 2 Cycles (28-Day Cycles) After Receiving Enzastaurin (LY317615)…